Patent intelligence · CA
CA 2513044
PEPTIDES DE LIAISON KDR ET VEGF/KDR ET LEUR UTILISATION A DES FINS DIAGNOSTIQUES ET THERAPEUTIQUES
PEPTIDES DE LIAISON KDR ET VEGF/KDR ET LEUR UTILISATION A DES FINS DIAGNOSTIQUES ET THERAPEUTIQUES
Patent details — CA 2513044
- Jurisdiction
- CA
- Status
- expired
- Grant date
- Aug 5, 2004
- Expiration
- Jul 31, 2024
- Applicant
- DYAX CORP [US]
- CPC classes
- A61K 48/ 00 A I, A61K 49/ 22 A I, A61K 51/ 08 A I, A61K/4762
Quick answer
CA 2513044 (PEPTIDES DE LIAISON KDR ET VEGF/KDR ET LEUR UTILISATION A DES FINS DIAGNOSTIQUES ET THERAPEUTIQUES) is held by DYAX CORP [US]. Status: expired. Granted Aug 5, 2004. Expires Jul 31, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- DYAX CORP [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 48/ 00 A I, A61K 49/ 22 A I, A61K 51/ 08 A I, A61K/4762, A61K/49221, A61K/49223
More from DYAX CORP [US]
Related pharmaceutical patents in our USPTO index.
-
IL 172160
Method for non-invasive quantification of perfusion in a tissue
granted -
EP 2117603
TARGETING UND THERAPEUTISCHE VERBINDUNGEN UND GASGEFÜLLTE MIKROVESIKEL MIT DIESEN VERBINDUNGEN
granted -
WO 2009076388
CONJUGUÉS VECTEUR DE CIBLAGE - PHOSPHOLIPIDE
granted -
CA 2670932
DETECTION DU DETACHEMENT D'UN AGENT DE CONTRASTE IMMOBILISE DANS DES APPLICATIONS D'IMAGERIE MEDICALE
granted -
US 2008107607
TARGETING VECTOR-PHOSPHOLIPID CONJUGATES
granted -
US 2008063603
ULTRASOUND CONTRAST AGENTS AND METHODS OF MAKING AND USING THEM
granted -
CA 2631716
CONJUGUES VECTEUR DE CIBLAGE-PHOSPHOLIPIDES
granted -
US 2007128117
Ultrasound contrast agents and process for the preparation thereof
granted
Frequently asked questions
What is US patent 2513044?
CA 2513044 (PEPTIDES DE LIAISON KDR ET VEGF/KDR ET LEUR UTILISATION A DES FINS DIAGNOSTIQUES ET THERAPEUTIQUES) is held by DYAX CORP [US]. Status: expired. Granted Aug 5, 2004. Expires Jul 31, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2513044?
DYAX CORP [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 2513044 expire?
Our index shows an expiration date of Jul 31, 2024 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.